Compare ALRM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALRM | MLYS |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2015 | 2023 |
| Metric | ALRM | MLYS |
|---|---|---|
| Price | $45.72 | $27.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $57.00 | $47.33 |
| AVG Volume (30 Days) | 385.3K | ★ 988.0K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.42 | N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $1,011,187,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | $18.53 | ★ N/A |
| Revenue Growth | ★ 7.59 | N/A |
| 52 Week Low | $44.71 | $8.24 |
| 52 Week High | $61.40 | $47.65 |
| Indicator | ALRM | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 36.37 |
| Support Level | $44.71 | $26.85 |
| Resistance Level | $46.86 | $28.64 |
| Average True Range (ATR) | 1.56 | 1.54 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 18.09 | 21.55 |
Alarm.com Holdings Inc has a cloud-based platform that offers an expansive suite of IoT solutions addressing world-wide opportunities in the residential, multi-family, small business and enterprise commercial markets. It has two reportable segments: Alarm.com & Other. The Alarm.com segment represents the cloud-based Software platforms for intelligently connected property & related solutions. The other segment is focused on researching, developing & offering residential & commercial automation solutions & energy management products & services in adjacent markets. The majority of revenue is from the Alarm.com segment. The platform allows home & business owners to secure their properties and automate & control an array of connected devices.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.